The therapeutic role of isotretinoin in the management of Behçet's disease: A single-blinded, controlled therapeutic study

Journal of Drugs in Dermatology

Volumn 12, Issue 4, 2013, Pages

  Sharquie, Khalifa E ^a   Helmi, Raad M A ^b   Noaimi, Adil A ^c   Hayani, Raafa K ^d   Kadhom, Mohand A A ^e  

^a Scientific Council of Dermatology and Venereology   (Iraq)

^b MUSTANSIRIYAH UNIVERSITY   (Iraq)

^c UNIVERSITY OF BAGHDAD   (Iraq)

^d BAGHDAD TEACHING HOSPITAL   (Iraq)

^e General Directorate of Health   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; ISOTRETINOIN; RETANE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MOUTH ULCER; REMISSION; SINGLE BLIND PROCEDURE; SKIN DISEASE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BEHCET SYNDROME; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; IRAQ; ISOTRETINOIN; MALE; MIDDLE AGED; REMISSION INDUCTION; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875849965     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Al-Araji AH. History, epidemiology and diagnostic (classification) criteria. In: Al-Rawi ZS, Sharquie KE, Al-Araji AH, eds. Behcet's Disease: Clinical Aspects. Baghdad, Ihra: 2002:1-8.
2. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçe's dis-reproduction or use of any portion of the contents of these m ease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267-279.
3. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factor of poor visual outcome in Behçet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1147-1152. (Pubitemid 43124166)
4. Yazici H, Esen F. Mortality in Behçet's syndrome. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S138-40.
5. Yorizzo JL. Behçet's disease. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill Book Company; 1999:2161-2165.
6. Sharquie KE. Suppression of Behçet's disease with dapsone. Br J Dermatol. 1984;110(4):493-494.
7. Kannan G, Vasantha J, Rani NV, et al. Drug usage evaluation of dapsone. Indian J Pharm Sci. 2009;71(4):456-460.
8. Ghate J, Jorizzo J. Behçet's disease and complex aphthosis. J Am Acad Dermatol. 1999;40(1):1-18.
9. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother. 2004;5(2):317-328.
10. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behçet's disease: a double blind cross-over study. J Dermatol. 2006;33(8):541-546. (Pubitemid 44154792)
11. Alpsoy E. New evidence-based treatment approach in Behçet's disease. Patholog Res Int. 2012;2012:871019.
12. Alpsoy E, Akman A. Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301(10):693-702
13. Alpsoy E. Behçet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23(4):532-539. (Pubitemid 41447628)
14. Chams-Davatchi C, Barikbin B, Shahram F, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behçet's disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13(3):253-258.
15. Köse O, Dinç A, Simsek I. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease. Dermatology. 2009;218(2):140-145.
16. Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behçet's disease. Yonsei Med J. 2007;48(4):573-585.
17. Conklin RJ, Blasberg B. Common inflammatory diseases of the mouth. Int J Dermatol. 1991;30(5):323-335.
18. Saxen MA, Ambrosius WT, Rehemtula al-KF, Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):356-361 (Pubitemid 127670986)
19. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335(8697):1078-1080.
20. Malvasi A, Tinelli A, Buia A, De Luca GF. Possible long-term teratogenic effect of isotretinoin in pregnancy. Eur Rev Med Pharmacol Sci. 2009;13(5):393-396.
21. Sharquie KE, Al-Araji A, Hatem A. Oral pathergy test in Behçet's disease. In Bang D, Lee SS, Lee SS, eds. Proceedings of the 8th and 9th International Conference on Behcet's Disease. 2001:299-302
22. Sharquie KE. Behcet's disease. Postgraduate Doctor Middle East J. 1990;13:186-190
23. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology. 2006;45(3):348-352 (Pubitemid 43372853)
24. Sharquie KE, Al-Hayani RK. Re-evaluation of pathergy test in patients with Behçet's disease [diploma thesis]. Department of Dermatology and Venereology, College of Medicine, Baghdad University; 2002.
25. Al-Rawi ZS, Sharquie KE, Khalifa SJ, Al-Hadithi FM, Munir JJ. Behçet's disease in Iraqi patients. Ann Rheum Dis. 1986;45(12):987-990.
26. Ozdemir M, Balevi S, Deniz F, Mevlitoglu I. Pathergy reaction in different body areas in Behcet's disease. Clin Exp Dermatol. 2007;32:(1)85-87 (Pubitemid 46006375)
27. Sharquie KE, Al-Araji A, Hatem A. Oral pathergy test in Behçet's disease. Br J Dermatol. 2002;146(1):168-169. (Pubitemid 34158438)
28. Sharquie KE, Al-Araji A, Hatem A. Oral pathergy test [abstract]. Yonsei Med J. 2000;41(3 Suppl):41
29. Sharquie KE, Hatem A. Behcet's disease in Iraqi patients: A prospective study from a newly established multidiscipline Behçet's disease clinic and oral pathergy test as a new technique. Thesis submitted to: Scientific Committee of Dermatology and Venereology, Iraqi Commission for Medical Specializations in Dermatology and Venereology, 2001; Baghdad, Iraq.
30. Adinolfi M, Lehner T. Acute phase proteins and C9 in patients with Behçet's syndrome and aphthous ulcers. Clin Exp Immunol. 1976;25(1):36-39
31. Abu-Raghif AR. Dapsone in the treatment of Behçet's disease: A double-blind, placebo-controlled, cross-over study. MSc Thesis, Clinical Pharmacology, College of Medicine, Baghdad University, 2000.
32. Landau M, Mesterman R., Ophir J, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol. 2001;81(5):350-352. (Pubitemid 34015491)
33. Leadchman SA, Insogna KL, Katz, L, Ellison A, Milstone LM. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol. 1999;135(8):961-965. (Pubitemid 29382435)
34. Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 1998;39(4 Pt 2):S124-S128. (Pubitemid 28485161)
35. Fathy A, Mohamed RW, Ismael NA, El-Akhras MA. Expression of toll-like receptor 2 on peripheral blood monocytes of patients with inflammatory and noninflammatory acne vulgaris. Egypt J Immunol. 2009;16(1):127-134
36. Czeczuga-Semeniuk E, Anchim T, Dziecioł J, Dabrowska M, Wołczynski S. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells? Acta Biochim Pol. 2004;51(3):733-745. (Pubitemid 39296927)
37. Can M, Direskeneli H. Musculoskeletal and vascular involvement in Behçet's disease. Turkderm-Archives of the Turkish Dermatology and Venerology 2009;43(suppl 2):54-60.